Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asp-3026. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK known ✓ | Q9UM73 | 17/20 | 1.00 |
| ▸ | INSR | P06213 | 6/20 | 1.00 |
| ▸ | IGF1R | P08069 | 6/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | PTK2B | Q14289 | 3/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | ERN1 | O75460 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | FER | P16591 | 2/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asp-3026 SCHEMBL31142530 | 1.00 | ALK (1.00) | ALKINSRIGF1REGFRPTK2 | |
| Asp-3026 SCHEMBL2827739 | 1.00 | ALK (1.00) | ALKINSRIGF1REGFRPTK2 | |
| Asp-3026 SCHEMBL30090555 | 1.00 | ALK (1.00) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866379 | 0.97 | ALK (0.94) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866342 | 0.95 | ALK (0.91) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866398 | 0.94 | ALK (0.90) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866485 | 0.94 | ALK (0.89) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866656 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL2823904 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14866411 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 647 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12631641-B2 | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| CN-122005807-A | Application of HGF receptor inhibitor in preparation of medicine for treating/preventing myasthenia gravis | 重庆医科大学附属第一医院 | 2026-05-12 | — | — | CN | claimed |
| US-12522873-B2 | ALK and NTRK1 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| WO-2025238172-A1 | COMBINATIONS OF BRAF AND ALK/TRK INHIBITORS FOR COLORECTAL CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | claimed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250146076-A1 | ALK GENE FUSIONS AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-20250129429-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2025-04-24 | — | — | US | claimed |
| US-20250057963-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-02-20 | — | — | US | claimed |
| WO-2024249331-A1 | COMBINED RTK AND ALK INHIBITION IN RTK DRIVEN CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2023059801-A1 | BIOMARKERS FOR EGFR-MEDIATED RESISTANCE IN ONCOGENE-DRIVEN CANCERS AND METHODS OF TREATING, PREVENTING, AND/OR AMELIORATING ONCOGENE-DRIVEN CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-04-13 | — | — | WO | claimed |
| US-20230101403-A1 | METHOD OF TREATING OR AMELIORATING CANCERS DRIVEN BY RECEPTOR TYROSINE KINASE FUSION ONCOGENES, AND COMPOSITIONS FOR THE SAME | UNIV PENNSYLVANIA (US) | 2023-03-30 | — | — | US | claimed |
| WO-2023039539-A1 | GENE FUSIONS IN SARCOMA | FOUNDATION MEDICINE, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| WO-2022225995-A1 | METHODS AND SYSTEMS FOR GENE ALTERATION PREDICTION FROM PATHOLOGY SLIDE IMAGES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-10-27 | — | — | WO | claimed |
| US-20220267854-A1 | EGFR AND ROS1 KINASE IN CANCER | CELL SIGNALING TECHNOLOGY, INC. (US) | 2022-08-25 | — | — | US | claimed |
| WO-2022165214-A1 | METHODS OF TREATING CANCER WITH KINASE INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-04 | — | — | WO | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| WO-2022147163-A1 | ALK FUSION GENES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | claimed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | ALK 171/4885INSR 2259/4885IGF1R 3166/4885 |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | ALK 200/4885INSR 2582/4885IGF1R 3025/4885 |
| US-20250057963-A1 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | CDK10, CDK20, CDK9 | ALK 619/4885INSR 3500/4885IGF1R 1939/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | ALK 171/4885INSR 2259/4885IGF1R 3166/4885 |
| US-12631641-B2 | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker | ALK, BCR, ROS1 | ALK 1/4885INSR 4622/4885IGF1R 1310/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ALK 1479/4885INSR 1254/4885IGF1R 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.